Supreme Court temporarily restores nationwide access to mifepristone via telehealth and mail

The future of telehealth access to the abortion pill mifepristone remains uncertain as the FDA conducts a safety review of the drug. lawsuit Joe Raedle/Getty Images The Supreme Court temporarily paused a lower court decision to restrict nationwide access to the abortion pill mifepristone. A Louisiana lawsuit challenging mail-order mifepristone prescriptions remains on pause while the FDA completes its own review of the drug’s safety. Medication abortion now accounts for nearly two-thirds of all U.S. abortions, with telehealth delivering one in four — a share that could shrink if the FDA’s safety framework changes. The fate of nationwide access by mail for the abortion pill mifepristone has returned to the U.S. Supreme Court. On May 4, Justice Samuel A. Alito Jr. temporarily halted a recent lower-court ruling that restricted nationwide access to the abortion pill by mail — at least for now. The Supreme Court’s ruling reverses a May 1 decision by the 5th Circuit Court of Appeals in New Orleans, which ruled in favor of a Louisiana lawsuit that dispensing the abortion pill via telehealth threatens the safety of pregnant people. Louisiana currently bans abortion in almost all instances. The lower court’s ruling also attempted to block access to dispensing the drug by mail for miscarriage management and other non-abortion procedures. The ruling sowed confusion and chaos among providers and patients alike. Justice Alito’s order issued a temporary pause until at least May 11.  Last month, a Louisiana judge paused a lawsuit challenging mail access to mifepristone until the a Food and Drug Administration completes its review of whether its own safety requirements for the drug are sound. According to U.S. District Judge David Joseph’s decision, the FDA has 60 days to update the court on its review of the REMS rules, which dictate who can prescribe the drug and whether it can be mailed. The agency has six months to finish. In a post on X, Louisiana Attorney General Liz Murrill said she asked the Fifth Circuit to suspend the 2023 rules, arguing the state “is likely to succeed in showing that the 2023 REMS is unlawful.” “Decades of evidence and research from the U.S. and around the world show that mifepristone is safe and effective,” Amy Friedrich-Karnik, director of federal policy at the Guttmacher Institute, told Healthline in April. “These medications are so safe, they can be used as over-the-counter medications (and are in other countries),” said Sarah Prager, MD, an OB-GYN at University of Washington Medical Center. Friedrich-Karnik called the FDA review a “sham” designed to cut off access. Murrill said Louisiana is likely to win. The Fifth Circuit will hear arguments next. For the estimated 1 in 4 people currently seeking abortion through telehealth, the outcome will determine whether this remains an option. “While this case is paused and mifepristone access remains unchanged for now, we know the fight is far from over. The judge’s ruling leaves the door open for future restrictions to mifepristone access, said Alexis McGill Johnson, president and CEO, Planned Parenthood Federation of America (PPFA), in a statement shared with Healthline. “From the courts to the Trump administration to state legislatures across the country, mifepristone and abortion access are very much still under attack. Planned Parenthood organizations will continue to fight for patients to have the freedom to access care that is safe and effective — free from political interference,” McGill Johnson continued. 1 in 4 rely on telehealth abortion Medication abortion is how most people in the United States end a pregnancy, according to the Centers for Disease Control and Prevention (CDC). The method accounted for 63% of all abortions in 2023, according to Guttmacher Institute data. Medication abortion involves two drugs taken days apart. “Mifepristone is a medication that competitively binds to progesterone receptors and thus prevents progesterone from maintaining a pregnancy. When used in combination with misoprostol, it is a safe and highly effective way to help the uterus expel a pregnancy for either abortion or miscarriage,” Prager told Healthline. Misoprostol is taken 24 to 48 hours after mifepristone. By the end of 2024, 1 in 4 people received their abortion through telehealth, according to the Society of Family Planning. Through a telehealth appointment, a provider reviews a person’s medical history, confirms eligibility, and issues a prescription — all without an in-person visit.“Providers will take a really thorough health history to screen for allergies, worrisome pregnancy complications like ectopic pregnancy, anemia, or contraindications to medication abortion,” Alyssa Sherer, DNP, a medical consultant to the Abortion Coalition for Telemedicine, told Healthline. Guttmacher later estimated that in 2025, residents of the 13 states with total abortion bans received about 91,000 telehealth abortions, including about 9,350 in Louisiana. The state has already issued the first post-Dobbs criminal indictment of an abortion provider — a New York physician who prescribed pills via telehealth to a Louisiana teenager. “Reimposing barriers on mifepristone use would upend abortion provision nationwide, deepen racial and socioeconomic inequities in who can access care, and place additional strain on providers who are already navigating a fractured landscape,” said Friedrich-Karnik. As abortion clinics close, telehealth and urgent care fill gaps Part of what’s driving demand for telehealth abortion is the disappearance of local abortion clinics. When Planned Parenthood in Marquette, Michigan, closed last spring, it left about 1,100 patients without an in-person provider. “It’s a 500-mile stretch of no access,” Shawn Brown, MD, told Kaiser Family Foundation Health News. Brown, who described herself as ‘individually pro-life,’ added medication abortions to her urgent care practice to fill the gap.“This preference for telemedicine is often due to barriers to care that are created by stigma, time, jobs, children, school, geography, ability, or many other aspects,” Prager said. “Telemedicine is a safe and evidence-based way to get care for both miscarriage and abortion.” When asked how a telehealth abortion appointment differs from any other virtual visit, Sherer said, “They look pretty much the same.” Once the health history is reviewed, she explained, the provider sends prescriptions to a mail-order or retail pharmacy, and the patient can stay in touch with their provider throughout the process. Follow-up care, including confirming the abortion is complete, can also happen remotely. Abortion access across the United States varies widely from state to state. More information on finding access can be found here.

Click to expand Image Mifepristone at a Planned Parenthood clinic in Ames, lowa, US, July 18, 2024. © 2024 Charlie Neibergall/AP Photo The US Supreme Court paused on Monday an order by the country’s Fifth Circuit Court of Appeals that had inflicted a serious blow to abortion access nationwide. While the immediate danger was temporarily halted, the episode underscores a looming threat to abortion access posed by ongoing litigation in the United States. On May 1, the Fifth Circuit Court ruled that abortion providers could not remotely prescribe mifepristone and mail it to patients until a lawsuit brought by the state of Louisiana is resolved. Mifepristone is a safe and effective medication widely used for abortion and miscarriage care which has been available via telehealth and mail in the United States since 2023. Providers briefly halted the shipment of medication until the Supreme Court intervened on Monday. The high court reinstated telehealth access to the medication until May 11, with plans to provide further guidance by that date.Since the Supreme Court overturned the right to abortion in 2023, requests for abortion care via telehealth have doubled. A 2026 report by the Guttmacher Institute found people in states with abortion bans increasingly access abortions via telehealth, often from providers based in other states with shield laws protecting those who assist with abortion services. Women in the United States already face real health consequences, including preventable deaths, due to abortion care being denied or delayed. Ending telehealth provision would greatly worsen this crisis, especially for women and girls with limited financial resources, or with disabilities, and those living in states with abortion bans or in rural areas.Louisiana, 1 of 13 US states with a complete abortion ban, brought the case against the Food and Drug Administration (FDA), arguing that allowing mifepristone to be mailed undermined the state’s ban. A district court had paused the case in April pending an FDA review.Meanwhile, five additional states are pursuing two separate federal lawsuits challenging the use of mifepristone, despite more than two decades of safe use in the United States and nearly 100 other countries. The lower court ruling was a serious setback for reproductive rights in the United States; another blow in an ongoing series of attacks on autonomy and access to essential healthcare. The question of how much further reproductive rights will be rolled back in the Unites States is now before the courts.

Supreme Court Temporarily Restores Nationwide Access To Abortion Pill Update (05/04/2026): The U.S. Supreme Court on Monday issued a temporary order that restores full nationwide access to the abortion medication mifepristone, including through mail-order, telehealth prescriptions, and certified pharmacies, until at least May 11. The emergency ruling pauses a May 1 decision by the conservative 5th U.S. Circuit Court of Appeals that had reinstated a nationwide requirement for in-person dispensing only. That lower-court order had threatened to sharply restrict medication abortion access across the country, even in states where abortion remains legal. The USSC administrative stay came in response to emergency applications filed Saturday by mifepristone manufacturers Danco Laboratories and GenBioPro. The companies argued the 5th Circuit ruling would cause “immediate confusion,” “regulatory chaos,” and irreparable harm to patients and providers. Justice Samuel Alito, who handles emergency matters from the 5th Circuit, referred the matter to the full Court. Background Mifepristone, used in combination with misoprostol, accounts for approximately 60–70% of abortions in the United States and is also used for early miscarriage care. The FDA first approved the drug in 2000 and expanded access in 2016 and 2021, eventually allowing telehealth and mail delivery without an in-person visit requirement beginning in 2023. In June 2024, the Supreme Court unanimously rejected a previous challenge to the FDA’s rules, ruling that anti-abortion physicians lacked legal standing to sue. The new litigation was brought by Louisiana, which claimed standing as a state harmed by the federal regulations. What's Next The Supreme Court’s order maintains the status quo while the justices consider the manufacturers’ request for a longer stay or further review. A decision on whether to extend the relief beyond May 11 is expected in the coming days or weeks. The case could eventually return to the high court for full briefing and argument on the merits. The temporary restoration prevents an immediate nationwide disruption to medication abortion services at a time when the method has become the dominant form of abortion care following the 2022 Dobbs decision that overturned Roe v. Wade. Advocates on both sides are closely watching for further developments. Reproductive health groups welcomed the pause, while opponents of expanded access expressed disappointment that the 5th Circuit’s restrictions were not allowed to take effect immediately. The ruling marks the latest chapter in a years-long legal battle over one of the most widely used medications in reproductive health care. * * * Authored by Jacki Thrapp via The Epoch Times, Americans won’t be able to receive abortion drug mifepristone in the mail, according to a temporary ruling by the U.S. Fifth Circuit Court on May 1. “FDA conceded it had failed to adequately study whether remotely prescribing mifepristone is safe,” the three-judge panel in New Orleans ruled on Friday. The decision will block the drug from being shipped via mail until the Food and Drug Administration (FDA) can ensure the drugs are “safe and effective” before they can be marketed in the United States. Mifepristone, often called “the abortion pill,” is part of a two-drug regimen which allows a woman “to end a pregnancy up to 70 days into gestation,” according to Johns Hopkins University. The FDA first approved mifepristone in 2000, but doctors were only allowed to prescribe it after three in-person visits. The procedure changed in 2023 after the Biden administration expanded access to “medication abortion,” which provided a pathway for patients to avoid an in-person visit to the doctor and, instead, order the drug online to be shipped to their house. The state of Louisiana challenged the rule in 2025, arguing the justification for allowing this was based on “flawed or nonexistent data.” Louisiana alleged the medication “resulted in numerous illegal abortions” in the state and it also made women pay “thousands in Medicaid bills” for being harmed by mifepristone. Louisiana Attorney General Liz Murrill called Friday’s decision a “victory for life!” “The Biden abortion cartel facilitated the deaths of thousands of Louisiana babies (and millions in other states) through illegal mail-order abortion pills. Today, that nightmare is over, thanks to the hard work of my office and our friends at Alliance Defending Freedom,” Murrill wrote. “I look forward to continuing to defend women and babies as this case continues.” A bill to ban mifepristone was introduced by Sen. Josh Hawley (R-Mo.) in March. “The science is clear: The chemical abortion drug is inherently dangerous to women and prone to abuse. Yet major companies like Danco Laboratories are making billions off it,” Hawley said. Hawley’s bill would also allow women to sue manufacturers for damages if they are harmed by the chemical abortion. Rep. Delia C. Ramirez (D-Ill.) criticized the federal court decision on social media. “Mifepristone is safe and reliable,” Ramirez wrote in an X post on Friday. “IT SAVES LIVES.
 Extremist attempts to control our bodies and restrict our choices make women less safe. The right to make decisions about our bodies and our healthcare are OURS. They don’t belong in the hands of judges or politicians.” Tyler Durden Mon, 05/04/2026 - 11:04